Head to Head Survey: Recro Pharma (REPH) vs. Intercept Pharmaceuticals (ICPT)
Recro Pharma (NASDAQ: REPH) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
This is a summary of recent recommendations and price targets for Recro Pharma and Intercept Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Recro Pharma currently has a consensus target price of $13.50, suggesting a potential upside of 49.83%. Intercept Pharmaceuticals has a consensus target price of $153.85, suggesting a potential upside of 131.25%. Given Intercept Pharmaceuticals’ higher probable upside, analysts plainly believe Intercept Pharmaceuticals is more favorable than Recro Pharma.
Risk and Volatility
Recro Pharma has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of -2.1, meaning that its share price is 310% less volatile than the S&P 500.
This table compares Recro Pharma and Intercept Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Recro Pharma and Intercept Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Recro Pharma||$69.99 million||2.45||-$13.04 million||($2.21)||-4.08|
|Intercept Pharmaceuticals||$70.92 million||23.55||-$361.26 million||($15.50)||-4.29|
Recro Pharma has higher revenue, but lower earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
65.1% of Recro Pharma shares are held by institutional investors. Comparatively, 82.2% of Intercept Pharmaceuticals shares are held by institutional investors. 21.6% of Recro Pharma shares are held by insiders. Comparatively, 9.2% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Recro Pharma beats Intercept Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Recro Pharma
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.